Roivant Sciences (ROIV) Current Taxes (2022 - 2026)
Roivant Sciences' (ROIV) quarterly Current Taxes came in at $45.7 million in Q1 2026, up 10882.93% YoY from N/an in Q1 2025, and up 10882.93% on a QoQ basis from $416000.0 in Q1 2025.
Roivant Sciences (ROIV) Current Taxes (2022 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 5 years of Current Taxes data on file, last reported at $45.7 million in Q1 2026.
- Quarterly Current Taxes rose 10882.93% year-over-year to $45.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $45.7 million (up 10882.93% YoY) and the FY2026 annual result came in at $45.7 million, up 10882.93% from the prior year.
- Current Taxes grew to $45.7 million in Q1 2026, from $416000.0 in the prior quarter.
- In the past five years, Current Taxes ranged from a high of $45.7 million in Q1 2026 to a low of $416000.0 in Q1 2025.
- A 5-year average of $10.0 million and a median of $3.4 million in 2023 frame the typical range for Current Taxes.
- Annual changes were most pronounced in 2024 — Current Taxes plunged 97.72% — and 2026, when it jumped 10882.93%.
- Tracing ROIV's Current Taxes over 5 years: stood at $5.6 million in 2022, then jumped by 347.45% to $25.2 million in 2023, then sank by 97.72% to $576000.0 in 2024, then decreased by 27.78% to $416000.0 in 2025, then jumped by 10882.93% to $45.7 million in 2026.
- The last three Current Taxes figures came in at $45.7 million (Q1 2026), $416000.0 (Q1 2025), and $576000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 49.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 76.32 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 59,089.99 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 74.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 74.18 Mn |
| Mar 31, 2026 | 45.69 Mn |
| Mar 31, 2025 | 416,000.00 |
| Dec 31, 2024 | 576,000.00 |
| Sep 30, 2024 | 5.41 Mn |
| Jun 30, 2024 | 23.44 Mn |
| Mar 31, 2024 | 9.77 Mn |
| Dec 31, 2023 | 25.22 Mn |
| Sep 30, 2023 | 1.36 Mn |
| Jun 30, 2023 | 1.24 Mn |
| Mar 31, 2023 | 542,000.00 |
| Dec 31, 2022 | 5.64 Mn |
| Mar 31, 2022 | 708,000.00 |